Infliximab.
Infliximab (Remicade, Centocor, Inc.) is an intravenously administered monoclonal antibody to TNF proven effective in the treatment of moderate to severe Crohn's disease (CD). Its introduction in October 1998 was heralded by some as the most important addition to therapy for this condition in 50 years. Since then, additional indications have been added as efficacy has been proven in fistulising CD and in rheumatoid arthritis. Even though the costs associated with a single dose are several thousand US dollars, more than 150,000 patients have received infusions since its approval.
Valle
E
E
The Digestive Health Center, University of Virginia Health System, Charlottesville 22908, USA.
Gross
M
M
Bickston
S J
SJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D003424:Crohn Disease / Q000188:drug therapy*; D017277:Drug Approval; D017850:Economics, Pharmaceutical; D005544:Forecasting; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D017408:Guidelines as Topic; D006261:Headache / Q000139:chemically induced; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D009325:Nausea / Q000139:chemically induced; D010865:Pilot Projects; D012713:Serum Sickness / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab